Piper Sandler initiated coverage of Fennec (FENC) with an Overweight rating and $18 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Southpoint Trims Stake in Fennec Pharmaceuticals to 8%
- Fennec: Japanese PEDMARK Success and Debt Elimination Drive Upside Potential and Support Buy Rating
- Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment
- Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK
- Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan